Does assisted reproductive technology itself or polycystic ovary syndrome as a cause of infertility have any effect on first trimester serum screening results?

Journal of Reproductive Medicine

Volumn 57, Issue 3-4, 2012, Pages 129-135

  Köşüş, Aydin ^a   Köşüş, Nermin ^a   Duran, Müzeyyen ^a   Turhan, Nilgün Ö ^a  

^a FATIH UNIVERSITY   (Turkey)

Author keywords

Assisted; Assisted reproductive techniques; Crown rump length; First trimester screening; HCGbeta; Infertility; Nuchal translucency measurement; PAPP A; Polycystic ovary syndrome; Prenatal ultrasonography; Reproductive technology

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BIRTH WEIGHT; CONCEPTION; CONTROLLED STUDY; CROWN RUMP LENGTH; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FIRST TRIMESTER PREGNANCY; HORMONE BLOOD LEVEL; HUMAN; INFERTILITY THERAPY; NUCHAL TRANSLUCENCY MEASUREMENT; OVARY POLYCYSTIC DISEASE; PARITY; PREGNANT WOMAN; PRIORITY JOURNAL; SEROLOGY; BLOOD; CASE CONTROL STUDY; DOWN SYNDROME; ECHOGRAPHY; FETUS ECHOGRAPHY; METABOLISM; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDY;

ADULT; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; INFERTILITY, FEMALE; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; REPRODUCTIVE TECHNIQUES, ASSISTED; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, PRENATAL;

EID: 84860812255     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Snijders RJ, Noble P, Sebire N, et al: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998;352:343-346
2. Wald NJ, Rodeck C, Hackshaw AK, et al: First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:71-77
3. Orlandi F, Rossi C, Allegra A, et al: First trimester screening with free w-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 2002;22:718-721
4. Nicolaides KH: Nuchal translucency and other firsttrimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004;191:45-67
5. Cicero S, Bindra R, Rembouskos G, et al: Integrated ultrasound and biochemical screening for trisomy 21 at 11 to 14 weeks. Prenat Diagn 2003;23:306-310
6. Liao AW, Heath V, Kametas N, et al: First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 2001;16:1501-1504
7. Niemimaa M, Heinonen S, Seppala M, et al: First-trimester screening for Down's syndrome in in vitro fertilization pregnancies. Fertil Steril 2001;76:1282-1283
8. Ghisoni L, Ferrazzi E, Castagna C, et al: Prenatal diagnosis after ART success: The role of early combined screening tests in counselling pregnant patients. Placenta 2003;24:99-103
9. Bersinger NA, Wunder D, Vanderlick F, et al: Maternal serum levels of placental proteins after in vitro fertilization and their implications for prenatal screening. Prenat Diagn 2004;24:471-477
10. Maymon R, Shulman A: Integrated first-and secondtrimester Down syndrome screening test among unaffected IVF pregnancies. Prenat Diagn 2004;24:125-129
11. Hui PW, Tang MH, Lam YH, et al: Nuchal translucency in pregnancies conceived after assisted reproduction technology. Ultrasound Obstet Gynecol 2005;25:234-238
12. Orlandi F, Rossi C, Allegra A, et al: First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 2002;22:718-721
13. Tul N, Novak-Antolic Z: Serum PAPP-A levels at 10-14 weeks of gestation are altered in women after assisted conception. Prenat Diagn 2006;26:1206-1211
14. Anckaert E, Schiettecatte J, Sleurs E, et al: First trimester screening for Down's syndrome after assisted reproductive technology: Non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10-14 weeks of gestation. Fertil Steril 2008;90:1206-1210
15. Meschede D, Lemcke B, Stussel J, et al: Strong preference for non-invasive prenatal diagnosis in women pregnant through intracytoplasmic sperm injection (ICSI). Prenat Diagn 1998;18:700-705
16. Geipel A, Gembruch U, Ludwig M, et al: Genetic sonography as the preferred option of prenatal diagnosis in patients with pregnancies following intracytoplasmic sperm injection. Hum Reprod 1999;14:2629-2634
17. Azziz R, Carmina E, Dewailly D, et al: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245
18. American College of Obstetrics and Gynecology (ACOG): ACOG Educational Bulletin. Maternal Serum Screening, No. 228, September 1996 (replaces No. 154, April 1991). Int J Gynaecol Obstet 55:299-308
19. Kagan KO, Wright D, Spencer K, et al: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: Impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493-502
20. Bender F, Hecken J, Reinsberg J, et al: Altered first-trimester screening markers after IVF/ICSI: No relationship with small-for-gestational-age and number of embryos transferred. Reprod Biomed Online 2010;20:516-522
21. Engels MAJ, Kooij M, Schats R, et al: First-trimester serum marker distribution in singleton pregnancies conceived with assisted reproduction. Prenat Diagn 2010;30:372-377
22. Bellver J, Lara C, Soares SR, et al: First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction. Hum Reprod 2005;20: 2623-2627
23. Wojdemann KR, Larsen SO, Shalmi A, et al: First trimester screening for Down syndrome and assisted reproduction: No basis for concern. Prenat Diagn 2001;21:563-565
24. Orlandi F, Rossi C, Allegra A, et al: First trimester screening with free b-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 2002;22:718-721
25. Maymon R, Shulman A: Serial first-and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 2002;17:1081-1085
26. Ghisoni L, Ferrazzi E, Castagna C, et al: Prenatal diagnosis after ART success: The role of early combined screening tests in counselling pregnant patients. Placenta 2003;24:99-103
27. Weisz B, Rodeck CH: An update on antenatal screening for Down's syndrome and specific implications for assisted reproduction pregnancies. Hum Reprod Update 2006;12:513-518
28. Ranta JK, Raatikainen K, Romppanen J, et al: Increased timeto-pregnancy and first trimester Down's syndrome screening. Hum Reprod 2010;25:412-417
29. Zhong G, Chen B: Serum and follicular fluid levels of IGF-II, IGF-binding protein-4 and pregnancy-associated plasma protein-A in controlled ovarian hyperstimulation cycle between polycystic ovarian syndrome (PCOS) and non-PCOS women. Gynecol Endocrinol 2011;27:86-90. Epub 2010 Jun 8
30. Boldt HB, Conover CA: Pregnancy-associated plasma protein-A (PAPP-A): A local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res 2007;17: 10-18
31. Lawrence JB, Oxvig C, Overgaard MT: The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999;96:3149-3153
32. Clemmons DR: Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998;140:19-24
33. Aso Y, Okumura K, Wakabayashi S, et al: Elevated pregnancyassociated plasma protein-A in sera from type 2 diabetic patients with hypercholesterolemia: Associations with carotid atherosclerosis and toe-brachial index. J Clin Endocrinol Metab 2004;89:5713-5717
34. Conover CA, Harrington SC, Bale LK: Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells. Growth Horm IGF Res 2008;18:213-220
35. Ortiz CO, Chen B-K, Bale LK, et al: Transforming growth factor-ffregulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts. J Bone Miner Res 2003;18:1066-1072
36. Amato G, Conte M, Mazziotti G, et al: Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003;101:1177-1182
37. Tchkonia T, Lenburg M, Thomou T, et al: Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am J Physiol Endocrinol Metab 2007;292:298-307
38. Tchoukalova YD, Nathanielsz PW, Conover CA, et al: Regional variation in adipogenesis and IGF regulatory proteins in the fetal baboon. Biochem Biophys Res Commun 2009;380: 679-683
39. Peral B, San Millan JL, Castello R, et al: The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002;87:3977-3983
40. Villuendas G, San Millan JL, Sancho J, et al: The-597 G3A and-1743C polymorphisms in the promoter of the interleukin 6 gene (IL6) are associated with hyperandrogenism. J Clin Endocrinol Metab 2002;87:1134-1141